We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Monday
May 05
17:00 - 18:00
Brahms
Transformative radiotherapy by biomarker-driven treatment adaptation
Jan Bussink, The Netherlands;
Monica Mangoni, Italy
Proffered Papers are presented in one of the sessions scheduled in the main session halls. Each author will present orally for 7 minutes, followed by 3 minutes for discussion. Sessions will be recorded and available on-demand.
Proffered Papers
Interdisciplinary
Urology
17:00 - 17:10
A prospective randomized multicenter trial of Nimorazole as hypoxic modifier of accelerated chemo-radiotherapy for locally advanced HPV-neg HNSCC.
Vincent Grégoire, France
E25-4361
17:10 - 17:20
ARCADIAN: A TiTE-CRM phase I trial of tumour hypoxia modifier atovaquone with concurrent chemoradiation in non-small cell lung cancer (NCT04648033)
Michael Skwarski, United Kingdom
E25-2179
17:20 - 17:30
A pan-cancer characterisation of the hypoxic extracellular matrix identifies a gene signature predictive of radiotherapy benefit
Conrado Guerrero Quiles, United Kingdom
E25-2334
17:30 - 17:40
Artificial Intelligence impact on decision-making regarding short term ADT with prostate radiotherapy: ASTuTE clinical trial Interim results
Eric Wegener, Australia
E25-506
17:40 - 17:50
Longitudinal ADC Imaging for Treatment Response Prediction in Breast Cancer: Prognostic Radiomic Features and Related Functional Pathways
Xinyu ZHANG, China, Hong Kong Special Administrative Region
E25-634
17:50 - 18:00
Addressing Imaging and Biomarker-driven Uncertainty in Machine Learning-based Radiotherapy Outcome Prediction
Ali Ajdari, USA
E25-2757